Trade BioXcel Therapeutics, Inc. - BTAI CFD

Add to favourite

2.08

7.96%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.12

Long position overnight fee

-0.023512%

Short position overnight fee

0.00129%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	2.26
Open	2.24
1-Year Change	-36.18%
Day's Range	2.07 - 2.24

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Feb 21, 2025	2.08	-0.16	-7.14%	2.24	2.24	2.07
Feb 20, 2025	2.26	-0.08	-3.42%	2.34	2.38	2.21
Feb 19, 2025	2.31	0.05	2.21%	2.26	2.55	2.23
Feb 18, 2025	2.22	-0.08	-3.48%	2.30	2.33	2.15
Feb 14, 2025	2.28	-0.05	-2.15%	2.33	2.42	2.26
Feb 13, 2025	2.34	-0.40	-14.60%	2.74	2.74	2.11
Feb 12, 2025	2.75	0.29	11.79%	2.46	2.80	2.46
Feb 11, 2025	2.51	-0.34	-11.93%	2.85	2.85	2.48
Feb 10, 2025	2.93	-1.23	-29.57%	4.16	4.16	2.71
Feb 5, 2025	0.26	0.00	0.00%	0.26	0.26	0.26
Feb 4, 2025	0.29	0.00	0.00%	0.29	0.30	0.29
Feb 3, 2025	0.29	0.00	0.00%	0.29	0.29	0.29
Jan 31, 2025	0.30	0.00	0.00%	0.30	0.30	0.30
Jan 30, 2025	0.29	0.00	0.00%	0.29	0.29	0.29
Jan 29, 2025	0.32	0.00	0.00%	0.32	0.32	0.32
Jan 28, 2025	0.30	-0.02	-6.25%	0.32	0.32	0.30
Jan 27, 2025	0.35	0.04	12.90%	0.31	0.35	0.31
Jan 24, 2025	0.33	-0.06	-15.38%	0.39	0.42	0.32
Jan 23, 2025	0.34	0.02	6.25%	0.32	0.36	0.32
Jan 22, 2025	0.34	0.00	0.00%	0.34	0.39	0.33

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BioXcel Therapeutics, Inc. Company profile

About BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on drug development that utilizes artificial intelligence (AI) approaches to develop therapies in neuroscience and immuno-oncology. The Company's two advanced clinical development programs are BXCL501, an investigational, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine (Dex), for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment-naive to checkpoint inhibitors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioXcel Therapeutics Inc revenues was not reported. Net loss increased 30% to $106.9M. Higher net loss reflects General and administrative increase from $24.3M to $54.2M (expense), Interest income decrease of 72% to $44K (income), Interest expense increase of 48% to $40K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.79 to -$4.05.

Industry:

Bio Therapeutic Drugs

555 Long Wharf Dr
NEW HAVEN
CONNECTICUT 06511-6107
US

News

Microsoft Stock Price Forecast for 2025 and beyond: Third party price target

We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...

18:29, 7 February 2025

Ripple XRP price prediction: Third-party price target

Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com

15:29, 6 February 2025

Apple Store on Fifth Avenue, New York, October 2016

Apple (AAPL) stock price forecast: third-party price target

We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.

11:22, 6 February 2025